HUDDINGE, Sweden, July 9, 2003 (PRIMEZONE) -- Medivir: Interim Report, 1 January - 30 June 2003
- In May, Medivir reached a licensing agreement on MIV-210 with GlaxoSmithKline; EUR 6 m was received upon signing and up to EUR 86 m on the achievement on specific milestones, excluding royalties.
- CCS divested to the Segulah II L.P. investment fund as of 1 July 2003 for a price of SEK 210 m. This is a part of Medivir's strategy to fully focus on its R&D activities.
- Successes in the preclinical research have generated several new projects within areas with large need of therapies.
- Medivir's shares have been quoted on the Stockholm Exchange's Attract 40 list since 1 July.
- Profit after financial items was SEK -33.3 (4.3) m. Net sales stood at SEK 138.6 (165.5) m.
- CCS' net sales grew to SEK 85.6 (76.7) m. Profit after financial items was SEK 16.8 (9.6) m.
FOR MORE INFORMATION, PLEASE CONTACT: Rein Piir, CFO and VP IR, tel: +46 (0)70 853 7292
FORTHCOMING FINANCIAL INFORMATION
The Third-quarter Interim Report 2003 will be published on 23 October 2003.
Medivir's financial reports are available at its Website, www.medivir.se, under the 'Financial Information' heading.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2003/07/09/20030709BIT00090/wkr0001.doc
The full report
http://www.waymaker.net/bitonline/2003/07/09/20030709BIT00090/wkr0002.pdf
The full report
-0-